From the Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Cancer J. 2019 Jul/Aug;25(4):282-286. doi: 10.1097/PPO.0000000000000393.
Precision medicine incorporates information regarding tumor biology involved in patients' carcinogenesis and individualized treatment of patients using drugs that inhibit the molecular basis of their disease. Implementation of precision medicine accelerated the drug approval process, translating discoveries in basic science and biotechnology into patient care. Clinical trials with innovative or adaptive design including "basket" and "umbrella" trials explore personalized therapies against in selected tumor types and/or across tumor types. In 2007, we started the Initiative for Molecular Profiling and Advanced Cancer Therapy, the first precision medicine program across tumor types. We demonstrated that therapy matched to patients' tumor molecular profiling is associated with improved rates of response, progression-free survival, and overall survival compared with nonmatched targeted therapy. We have now entered a new era of precision medicine that includes comprehensive tumor testing and multiple innovative modalities hoping to overcome the complexity of tumor biology to improve patient outcomes.
精准医学整合了涉及患者致癌发生的肿瘤生物学信息,并使用抑制疾病分子基础的药物对患者进行个体化治疗。精准医学的实施加速了药物审批过程,将基础科学和生物技术的发现转化为患者护理。具有创新或适应性设计的临床试验,包括“篮子”和“伞式”试验,针对选定的肿瘤类型和/或跨肿瘤类型探索个性化治疗。2007 年,我们启动了跨肿瘤类型的分子分析和先进癌症治疗倡议,这是首个精准医学项目。我们证明,与非匹配的靶向治疗相比,针对患者肿瘤分子分析的治疗与更高的反应率、无进展生存期和总生存期相关。现在,我们已经进入了精准医学的新时代,包括全面的肿瘤检测和多种创新模式,希望克服肿瘤生物学的复杂性,改善患者的预后。